Recruiting

MISSIONExpanding Access to Preventive Chemotherapy for Neglected Tropical Diseases among Mobile and Migrant Populations in Nigeria

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate the reach, coverage, compliance, acceptability, and prevalence of preventive chemotherapy-targeted neglected tropical diseases among mobile and migrant populations in Nigeria, using a modified mass administration of medicines (MAM) strategy.

What is being tested

Modified Mass Administration of Medicines Strategy

+ Albendazole 400 mg

+ Praziquantel 40 mg/kg

OtherDrug
Who is being recruted

Vector Borne Diseases+25

+ Mosquito-Borne Diseases

+ Eye Diseases

Over 5 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Services Research Study

Interventional
Study Start: July 2026
See protocol details

Summary

Principal SponsorUwemedimo Friday Ekpo
Study ContactUwem Ekpo, PhDMore contacts
Last updated: July 16, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 2026

Actual date on which the first participant was enrolled.

Neglected tropical diseases (NTDs) are among the most common groups of diseases globally, affecting more than one billion people and disproportionately burdening remote, underserved, and marginalized populations. The World Health Organization (WHO) broadly classifies most NTDs into two categories based on their recommended management approaches. Case-management NTDs-including Buruli ulcer, human African trypanosomiasis, rabies, Guinea worm disease, lymphoedema, leprosy, trichiasis, leishmaniasis, yaws, dengue, and mycetoma-require individualized diagnosis and treatment because of management complexity or the absence of effective large-scale diagnostic and therapeutic tools. In contrast, preventive chemotherapy NTDs (PC-NTDs), such as onchocerciasis, schistosomiasis, lymphatic filariasis, trachoma, and soil-transmitted helminthiasis, are primarily controlled through mass drug administration (MDA) delivered to at-risk populations to reduce morbidity and interrupt transmission. Other NTDs that do not neatly fit within these categories, such as rabies, snakebite envenoming, and dengue, require alternative prevention and control approaches. In many endemic countries, PC-NTDs constitute the largest proportion of the NTD burden and therefore have well-established control programs. Over the last decade, NTDs have increasingly gained recognition as a major global health priority, culminating in the WHO NTD Road Map 2021-2030, which outlines ambitious targets for the control, elimination, or eradication of all NTDs in alignment with the Sustainable Development Goals. Despite these commitments, progress toward achieving the 2030 elimination targets for several PC-NTDs remains insufficient. In the African Region, where more than 40% of the global NTD burden is concentrated, only 19 of 54 countries had eliminated at least one NTD as of 2025. Persistent gaps in intervention coverage among vulnerable and underserved populations continue to threaten progress toward NTD elimination goals. Several programmatic bottlenecks have been identified, including but not limited to poor community awareness, perceived severity of the disease, perceived benefits of interventions, inadequate human and financial resources for programming, conflict and insecurity, political instability, and increasing migration and population mobility. While many of these barriers have received considerable global attention, migration and population mobility are increasingly emerging as critical yet understudied challenges. Population movement may occur because of conflict, insecurity, environmental pressures, seasonal labor, or other livelihood-related factors (trade, pastoralism, fishing, leisure, schooling), all of which may disrupt access to routine public health interventions. However, the specific implications of migration for MDA delivery, treatment continuity, and coverage remain poorly understood. Similarly, evidence-based strategies for optimizing PC-NTD programs among highly mobile and migrant populations remain limited. Nigeria, the most populous country in sub-Saharan Africa, accounts for approximately one-quarter of the continent's NTD burden and has yet to eliminate any major NTD. For more than a decade, our team has collaborated with the Nigerian government and implementing partners to support NTD elimination efforts across the country. Although substantial progress has been made in reducing disease prevalence, improving morbidity management, and responding to outbreaks, migration continues to pose a major challenge to achieving optimal treatment coverage and has received limited attention within existing elimination strategies. Population movement within Nigeria and across neighboring borders are often driven by seasonal climatic patterns, insecurity and economic opportunities, and is facilitated by extensive river systems, trade corridors, grazing routes, and arable lands that sustain economic activities. These populations, herein referred to as mobile and migrant populations (MMPs), are frequently absent during MDA campaigns. Consequently, they often experience non-treatment, limited awareness of MDA activities, limited engagement with health-workers, and increasing community fatigue. Collectively, these dynamics may contribute to treatment refusals, sustain disease transmission, and slow progress toward elimination goals. The investigators therefore posit the need to improve MDA access, reach, and coverage among MMPs through approaches that strengthen involvement, trust, ownership, and the perceived value of MDA among MMPs that have historically been underrepresented in routine health programs. This study aims to develop and evaluate a novel delivery model that utilizes community mapping and participatory research approaches to strengthen access to MDA among MMPs. The process will begin by generating a detailed understanding of migration realities, including migratory routes, movement timing, seasonal patterns, and key drivers of mobility, to identify where, when, and how MMPs move across different settings. The study will also explore the social and occupational networks that exist along these migratory pathways and assess how these networks can be strategically leveraged to expand MDA access and delivery. Ultimately, the overarching aim of the study is to evaluate whether this co-constructed delivery model can improve access, reach, and coverage of MDA among MMPs in Nigeria compared with standard delivery approaches. Specifically, the study will explore migratory routes, movement patterns, and drivers influencing participation in MDA; identify the social and occupational structures that shape mobility and access to healthcare; and examine how these existing networks can be strategically leveraged to improve MDA delivery, reporting, and community engagement. In addition, the study will assess the livelihood-linked incentives and complementary services prioritized by MMPs and evaluate how integrating these preferences into intervention design may strengthen demand for and participation in preventive chemotherapy programs. Finally, the study will examine the contextual, behavioral, and structural factors influencing implementation, while exploring how participatory processes foster trust, ownership, inclusivity, feasibility, sustainability, and scalability of the proposed delivery model across diverse migratory settings in Nigeria.

NCT07707817
Principal SponsorUwemedimo Friday Ekpo
Study ContactUwem Ekpo, PhDMore contacts
Last updated: July 16, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

5760 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Services Research Study

These studies look at how healthcare is delivered, managed, and organized. They aim to improve care quality, patient experience, and access to treatment.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 5 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Vector Borne DiseasesMosquito-Borne DiseasesEye DiseasesFilariasisHelminthiasisHemic and Lymphatic DiseasesLymphatic DiseasesLymphedemaNematode InfectionsParasitic DiseasesPathologic ProcessesSkin DiseasesSkin Diseases, InfectiousSkin Diseases, ParasiticPathological Conditions, Signs and SymptomsTrematode InfectionsEye InfectionsEye Infections, ParasiticSecernentea InfectionsSpirurida InfectionsSkin and Connective Tissue DiseasesDisease AttributesElephantiasis, FilarialInfectionsOnchocerciasisSchistosomiasisOnchocerciasis, OcularNeglected Diseases

Criteria

5 inclusion criteria required to participate
Provide informed consent or assent with parental/guardian consent where applicable for minors

Are children aged 5-14 years or adult heads of households residing in households identified as belonging to mobile or migrant populations

Are willing to provide the required biological specimens and participate in interviews, surveys, and participatory workshops or discussions as required by the study protocol

Reside permanently or semi-permanently within the study communities

Show More Criteria

5 exclusion criteria prevent from participating
Do not belong to the identified mobile or migrant populations targeted by the study

Are severely ill or have medical conditions that, in the opinion of study personnel, would make participation unsafe or inappropriate

Are unable or unwilling to provide the required biological specimens or participate in study procedures

Are temporary visitors without meaningful residence in the study communities

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Mobile and migrant populations in our context refer to individuals or groups who are frequently absent during mass drug administration (MDA) campaigns due to one or more factors, including conflict and insecurity, environmental pressures, seasonal labor migration, or livelihood-related activities such as trade, pastoralism, fishing, leisure, schooling, and other forms of mobility.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Recruitment is done at the Household level in selected communities

Ondo, NigeriaOpen Recruitment is done at the Household level in selected communities in Google Maps
Recruiting
One Study Center